150 related articles for article (PubMed ID: 30356164)
21. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature.
Dyba J; Tinmouth A; Bredeson C; Matthews J; Allan DS
Transfus Med; 2016 Jun; 26(3):202-7. PubMed ID: 27046441
[TBL] [Abstract][Full Text] [Related]
23. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
Gao F; Zhou X; Shi J; Luo Y; Tan Y; Fu H; Lai X; Yu J; Huang H; Zhao Y
Ann Hematol; 2020 Nov; 99(11):2679-2687. PubMed ID: 32519094
[TBL] [Abstract][Full Text] [Related]
24. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
25. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
26. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
Dickinson M; Cherif H; Fenaux P; Mittelman M; Verma A; Portella MSO; Burgess P; Ramos PM; Choi J; Platzbecker U;
Blood; 2018 Dec; 132(25):2629-2638. PubMed ID: 30305280
[TBL] [Abstract][Full Text] [Related]
27. Eltrombopag Add-on Treatment in a Child With Fanconi Aplastic Anemia Awaiting Hematopoietic Stem Cell Transplantation.
Aydin Koker S; Çalişkan Polat A
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e74-e76. PubMed ID: 33560087
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
[TBL] [Abstract][Full Text] [Related]
30. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Zhang J; Thapar M; Farrell C; Wire MB
Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
[TBL] [Abstract][Full Text] [Related]
32. [Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy].
Kanda M; Kondo M; Yamamoto S; Mukai M
Nihon Naika Gakkai Zasshi; 2013 Jun; 102(6):1461-3. PubMed ID: 23947214
[No Abstract] [Full Text] [Related]
33. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi T; Martin S; Worswick S
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
[TBL] [Abstract][Full Text] [Related]
34. Comment on: Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Akyay A; Öncül Y
Pediatr Blood Cancer; 2020 Sep; 67(9):e28304. PubMed ID: 33332023
[No Abstract] [Full Text] [Related]
35. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.
Ahn HJ; Byun JM; Kim I; Youk J; Koh Y; Shin DY; Hong J; Yoon SS
J Korean Med Sci; 2022 Feb; 37(6):e48. PubMed ID: 35166084
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag and serum of a different hue.
Cardamone D; Milone MC; Glaser L; Frey NV; Kricka LJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1175. PubMed ID: 23991726
[No Abstract] [Full Text] [Related]
40. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
